Francois Nader - May 10, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
May 10, 2022
Transactions value $
$921
Form type
4
Date filed
5/12/2022, 04:22 PM
Previous filing
May 2, 2022
Next filing
Jun 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $436K +23.1K +3285.92% $18.87 23.8K May 10, 2022 Direct F1
transaction MRNA Common Stock Sale -$435K -3.2K -13.43% $136.10 20.6K May 10, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -23.1K -58.16% $0.00 16.6K May 10, 2022 Common Stock 23.1K $18.87 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2022.
F2 Represents the number of shares sold by the Reporting Person to cover the payment of the exercise price of the option.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.10 to $136.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 This option is fully vested and exercisable.